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Abstract
Introduction: BAY 94-9027, a site-specifically PEGylated, B-domain‒deleted recom-
binant factor VIII (FVIII) with extended half-life, demonstrated efficacy for bleed 
prevention and treatment in previously treated adolescents and adults with severe 
haemophilia A.
Aim: To assess BAY 94-9027 in children with severe haemophilia A.
Methods: In the two-part PROTECT VIII Kids study, boys <12 years with <1% 
FVIII and >50 exposure days (EDs) to FVIII were enrolled in two cohorts (<6 years; 
6-<12 years) and treated with BAY 94-9027 prophylaxis twice-weekly, every 5 days, 
or every 7 days at physician discretion for ≥50 EDs (Part 1) or twice-weekly for 12-
weeks (Part 2). Annualized bleeding rate (ABR) was a primary efficacy endpoint; FVIII 
inhibitor development was the primary safety variable.
Results: At study completion, 25 patients had been treated twice-weekly, 28 in the 
every-5-day group, and 8 in the every-7-day group. Median ABR for all bleeds was 
2.9 (Part 1) and 2.4 (Part 2) and similar in younger and older patients; median ABR for 
joint bleeds was 0 for both cohorts. In the last 90 days’ treatment, median ABR was 
0 for younger and older patients (Part 1). Of 149 reported bleeds, 93% were treated 
with ≤2 infusions. Twelve patients, the majority <6 years (n = 11), discontinued due to 
apparent loss of efficacy or hypersensitivity. No FVIII inhibitors developed.
Conclusions: In PROTECT VIII Kids, which allowed tailoring of prophylaxis to indi-
vidual clinical response, BAY 94-9027 was efficacious for bleed prevention and treat-
ment in previously treated children with severe haemophilia A.
K E Y W O R D S
children, factor VIII, haemophilia A, polyethylene glycol, prophylaxis
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1  | INTRODUC TION
Factor VIII (FVIII) replacement therapy is the standard of care for 
severe haemophilia A. FVIII products with extended half-lives 
offer the potential for less frequent infusions than standard-act-
ing FVIII products and may decrease the burden of prophylaxis 
and improve adherence.1,2 BAY 94-9027 (damactocog alfa pegol; 
Jivi®; Bayer3) is a B-domain–deleted recombinant FVIII (BDD-
rFVIII) product that is site-specifically conjugated with a 60-kDa 
branched polyethylene glycol (PEG), resulting in one PEG per 
BDD-rFVIII protein. BAY 94-9027 has demonstrated an extended 
half-life (EHL) in children, compared with standard-acting FVIII 
products.4,5
In the phase 2/3 PROTECT VIII study, BAY 94-9027 demon-
strated effective prophylaxis in adults and adolescents with severe 
haemophilia A with dosing up to every 7 days.6 Assessing children 
as an independent population is necessary because of age-related 
differences in the pharmacokinetics of all FVIII products, which 
have a shorter half-life and faster clearance than in older patients.4 
BAY 94-9027 has a half-life of 19 hours in adults and adolescents,6 
which is reduced to 15-16 hours in children <12 years.4 Similar re-
ductions in half-life are seen for other EHL FVIII products in chil-
dren compared with adolescents and adults, including rFVIIIFc 
(Elocta®; Sobi)7 and glycoPEGylated turoctocog alfa (Espercot®; 
Novo Nordisk),8 and benefits relating to prolonged half-lives, such 
as longer dosing intervals, may not be as profound in patients 
aged <12 years. Age-related differences in physical activity levels 
are also seen, with younger patients being generally more active 
than older patients; this difference needs to be considered when 
determining appropriate prophylaxis dosing.9 Prevention of joint 
bleeding is particularly important in the paediatric population be-
cause of the relationship between joint bleeds and development of 
chronic arthropathy over time.10
The PROTECT VIII Kids study aimed to evaluate the efficacy and 
safety of BAY 94-9027 in previously treated children aged ≤12 years 
with severe haemophilia A.
2  | METHODS
2.1 | Patients
Boys <12 years with severe haemophilia A (FVIII <1%) and >50 
prior exposure days (EDs) to any FVIII product were eligible. Key 
exclusion criteria included the presence or history of FVIII inhibi-
tors (>0.6 Bethesda units [BU]/mL), any bleeding disorder other 
than haemophilia A, creatinine >2 times the upper limit of normal 
(ULN), aspartate aminotransferase or alanine aminotransferase 
>5 times ULN, platelet count <100 000/mm,3 or known hyper-
sensitivity to BAY 94-9027 or its components. Per guidelines for 
clinical investigation of FVIII products in children <12 years,11 
patients were enrolled across two age groups: <6 years and 
6-<12 years.
2.2 | Study design
PROTECT VIII Kids was a phase 3, multicentre, open-label, single-
arm study (NCT01775618), conducted from May 2013 to March 
2015 in two parts.
In the main study (Part 1), patients were treated with BAY 94-9027 
at one of three recommended dose intervals for ≥50 EDs and for a mini-
mum of 6 months. Doses were extrapolated from experience in adoles-
cents and adults in the phase 1 and phase 2/3 PROTECT VIII studies.4,12 
Patients received 25-60 IU/kg of BAY 94-9027 at least once per week; 
initial dosing recommendations were 25 IU/kg twice-weekly, 45 IU/kg 
every 5 days, or 60 IU/kg every 7 days. Investigators were encouraged 
to start with the least-frequent regimen that they believed was appro-
priate for the patient. Per protocol, the dose or dose frequency could be 
changed at any time, and dosage recommendations were provided if a 
patient experienced ≥2 breakthrough spontaneous muscle and/or joint 
bleeds within any 3-month period. Because the dose for every-7-day 
prophylaxis was not to exceed 60 IU/kg, patients in this group could 
only increase their dose frequency; patients treated twice-weekly 
could increase their dose, while those treated every 5 days could in-
crease either their dose or dose frequency.
A 12-week substudy (Part 2) enrolled 12 additional children 
<6 years to obtain further safety data owing to a higher-than-ex-
pected withdrawal rate in this age group in Part 1. Patients in Part 2 
received twice-weekly prophylaxis 25-60 IU/kg.
In Parts 1 and 2, BAY 94-9027 dosing for the treatment of break-
through bleeds was determined based on bleed severity, patient's 
past experience with treatment of bleeds, and physician recommen-
dations. Follow-up treatments were administered as needed.
Treatment data, bleeding episodes and response to treatment for 
breakthrough bleeds were recorded by the patient/parent or guard-
ian in an electronic patient diary. The study was conducted in ac-
cordance with the International Conference on Harmonization Good 
Clinical Practice Guidelines. The study protocol received approval by 
each site's independent ethics committee/institutional review board 
before patient enrolment. Written informed consent was obtained 
from patients' legal guardians before study entry; if appropriate, as-
sent was also obtained.
2.3 | Efficacy assessments
Primary efficacy variables in the main study (Part 1) included the 
annualized number of total bleeds during prophylactic treatment 
and assessment of response to treatment of bleeds. The annualized 
bleeding rate (ABR) for all bleeds (overall, joint, trauma and spon-
taneous) during prophylaxis was assessed in patients who achieved 
≥50 EDs (study completers). ABR also was evaluated during the last 
90 days of treatment to account for patients who changed prophy-
laxis dose or frequency during Part 1 of the study. The response 
to treatment of bleeds was evaluated by the patient or caregiver 
and was rated on a 4-point scale (excellent/good/moderate/poor).
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Patients in Part 2 who completed the 12-week observation pe-
riod were included in the efficacy evaluation of ABR.
2.4 | Safety assessments
In Part 1, the primary safety variable was development of FVIII 
inhibitors. Vital signs, physical examinations, laboratory safety, 
quantitative measurement of PEG and adverse events (AEs), in-
cluding hypersensitivity and loss of efficacy, were also recorded. 
Hypersensitivity was defined as an allergic reaction and indicated by 
angioedema, burning and stinging at the infusion site, chills, flushing, 
generalized urticaria, headache, hives, hypotension, lethargy, nau-
sea, restlessness, tachycardia, tightness of the chest, tingling, vomit-
ing or wheezing. Loss of efficacy was diagnosed clinically, based on 
the occurrence of unexpected bleeding events, absent or inadequate 
responses to treatment of a bleed, or abnormally low FVIII levels.
FVIII inhibitors were defined as antibodies specific for unmodi-
fied FVIII protein that inhibited FVIII activity. Development of FVIII 
inhibitors (≥0.6 BU/mL) was tested using a one-stage Nijmegen-
modified Bethesda assay, as described previously,12 on samples 
collected immediately before exposure to BAY 94-9027, after 
10-15 EDs, after 50 EDs, and at any time inhibitor development was 
suspected.
Anti-drug antibodies were defined as antibodies directed against 
PEG that were specific for BAY 94-9027 and did not cross-react 
with unmodified FVIII. Patients were monitored for anti-BAY 94-
9027 antibodies using an enzyme-linked immunosorbent assay at 
baseline; months 1, 2 and 3; and at the final visit. If results were 
positive, further investigations were conducted to determine if the 
antibody was against PEG or FVIII and if the anti-PEG antibody sub-
type was immunoglobulin (Ig) M or IgE. Quantitation of free PEG in 
plasma was performed using a combination of size-exclusion chro-
matography and mass spectrometry at baseline and the final visit 
(the lower limit of quantification [LLOQ] was 0.1 mg/L).
In Part 2, the primary safety outcome was to characterize the 
potential immune response to BAY 94-9027 previously observed in 
Part 1, and to evaluate the type of antibodies against PEG. Patients 
in Part 2 completed weekly visits for physical examination and AEs. 
Testing for FVIII inhibitors was performed on samples collected at 
baseline and final visit; anti-BAY 94-9027 antibody testing was per-
formed for samples collected at all visits except for Visit 9.
In Part 1 and 2, all laboratory analyses were performed by spe-
cialized central laboratories.
2.5 | Statistical analysis
Sample size (n ≥ 25 patients per age group) was determined accord-
ing to the requirements set forth by the European Medicines Agency 
guidelines for investigations of FVIII products.11 Statistical analyses 
were descriptive and performed using SAS software 9.1 or higher 
(SAS Institute Inc). Summary statistics were calculated for con-
tinuous data, and frequencies were calculated for categorical data. 
Subgroup analyses were performed to determine ABR for patients 
who increased their dose or changed dosing frequency and once a 
TA B L E  1   Demographics and baseline characteristics (safety population)
 
Part 1
Part 2
Aged < 6 y
(N = 12)
Aged < 6 y
(n = 32)
Aged 6-<12 y 
(n = 29)
Total
(N = 61)
Age, y
Median (range) 3.0 (2-5) 9.0 (6-11) NA 4.0 (2-5)
Race, n (%)
White 27 (84.4) 28 (96.6) 55 (90.2) 10 (83.3)
Black 3 (9.4) 0 3 (4.9) 0
Asian 1 (3.1) 1 (3.4) 2 (3.3) 1 (8.3)
American Indian or Alaska native 1 (3.1) 0 1 (1.6) 0
Native Hawaiian or other Pacific Islander 0 0 0 1 (8.3)
BMI, kg/m2
Median (range) 15.5 (13-18) 16.4 (13-22) NA 15.3 (14-17)
Previous treatment, n (%)
Prophylaxis 31 (96.9) 25 (86.2) 56 (91.8) 12 (100)
On demand 1 (3.1) 4 (13.8) 5 (8.2) 0
Patients with target joints, n (%) 1 (3.1) 10 (34.5) 11 (18.0) 0
Bleeds in the previous 12 mo, median (Q1; Q3) 1 (1.0; 5.0) 4.0 (2.0; 10.5) 3.0 (1.0; 9.0) 3.5 (0.5; 5.5)
Joint bleeds in the previous 12 mo, median (Q1; Q3) 0 (0; 1.0) 2.0 (0.5; 5.0) 1.0 (0; 3.0) 0 (0; 2.0)
Abbreviations: BMI, body mass index; mo, months; NA, not available; Q1, quartile 1; Q3, quartile 3; y, years.
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stable dose was achieved. All patients who received ≥1 dose of BAY 
94-9027 were included in the safety analysis.
3  | RESULTS
A total of 61 patients from 31 centres in 13 countries received 
BAY 94-9027 in Part 1 (<6 years, n = 32; 6-<12 years, n = 29). 
Twelve patients from seven centres in six countries received BAY 
94-9027 in Part 2. Demographic and clinical characteristics are 
shown in Table 1.
In Part 1, 18 patients were assigned by the investigator to twice-
weekly dosing, 27 patients to every-5-day dosing, and 16 patients to 
every-7-day dosing (Figure 1). In the twice-weekly group, 3 patients 
discontinued, and the remaining patients maintained the same dosing 
frequency. In the every-5-day prophylaxis group, 4 patients discon-
tinued and 1 patient reduced his dosing frequency to every 7 days. 
Eight patients in the every-7-day group switched to more-frequent 
dosing, and 1 patient discontinued after experiencing hypersensi-
tivity with the first dose of BAY 94-9027 but was included in the 
safety analysis. At study completion, there were 17 patients in the 
twice-weekly group, 28 in the every-5-day group, and 8 patients in 
the every-7-day group for Part 1 (Figure 2). Overall, 53 of 61 treated 
patients (87%) in Part 1 completed ≥50 EDs, and 44 (72%) remained 
on their initial dosing frequency. Eight patients completed Part 2, 
and 59 patients from Part 1 and Part 2 continued in the PROTECT 
VIII Kids extension study.13
Patients enrolled in Part 1 excluding the patient who discontin-
ued after one ED had a mean ± standard deviation (SD; range) time 
in study of 233.6 ± 77.1 (15-448) days and accumulated a mean ± SD 
(range) of 50.0 ± 17.0 (3-68) EDs. Mean ± SD adherence across treat-
ment groups was 99.6% ± 8.01% among the patients who completed 
≥50 EDs during Part 1. Patients in Part 2 had a mean ± SD (range) 
time in the study of 65.7 ± 21.8 (31-86) days and accumulated a 
mean ± SD (range) of 18.1 ± 10.4 (3-30) EDs. The mean total dose in 
each treatment group is presented in Figure 3.
3.1 | Efficacy
In 53 patients who completed Part 1, the median (Q1; Q3) ABR for all 
bleeds was 2.9 (1.1; 6.1) and was similar in both age cohorts (Table 2 
and Figure 3); median ABRs (Q1; Q3) for joint bleeds and spontane-
ous bleeds were 1.0 (0.0; 2.0) and 0.0 (0.0; 2.6), respectively. Twelve 
patients (22.6%) had 0 bleeds: four patients <6 years and eight pa-
tients 6-12 years.
F I G U R E  1   PROTECT VIII Kids study design. Part 1 starting dosing regimen of each patient was not randomized and selected by the 
investigator. Maximum age for subgroup 1 = 12 y minus 1 d when consent was signed; maximum age for subgroup 2 and Part 2 = 6 y minus 
1 d when consent was signed. ED, exposure day; y, years
Subgroup 1
Age 6 to <12
y (n = 29)
Subgroup 2
Age <6 y
(n = 32)
Age <6 y
(n = 12)
Week −6
Screening period
bleeds treated using
patient’s own
medication
Bleeds treated with
BAY 94–9027
Week 0 Week 12 Minumum of 50 EDs
(≥6 mo)
Pa
rt
 1
(M
ai
n 
st
ud
y)
Pa
rt
 2
(S
ub
st
ud
y)
25 IU/kg twice weekly (n = 10)
45 IU/kg every 5 d (n = 15)
65 IU/kg every 7 d (n = 4)
25 IU/kg twice weekly (n = 8)
25 IU/kg twice weekly (n = 12)
45 IU/kg every 5 d (n = 12)
65 IU/kg every 7 d (n = 12)
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Nine patients in Part 1 changed dosing frequency (Figure 2); for 
eight patients who switched from every-7-day dosing to more-fre-
quent dosing, median ABR for all bleeds improved (Figure 4), and 
the median (Q1; Q3) number of all bleeds improved from 2.0 (1.0; 
6.0) to 1.0 (0; 2.0). ABR for spontaneous, joint and trauma bleeds 
was also reduced after switching to more-frequent dosing. Median 
(Q1; Q3) ABR also improved in patients who increased their dose 
but did not change dosing frequency (twice-weekly arm [n = 6], 
11.5 [2.2; 26.1] vs 1.4 [0; 10.0], before and after changing dose, 
respectively; every-5-day arm [n = 11], 11.1 [4.4; 19.2] vs 1.7 [0; 
4.2]).
Comparison of ABR for all bleeds in the first 90 days vs the last 
90 days of participants who completed Part 1 indicated that bleed-
ing control markedly improved in both age cohorts as dosing regi-
mens were adapted (Figure 5).
Of 140 bleeds reported during Part 1 of the study, 92% were 
controlled with one or two infusions of BAY 94-9027; response to 
treatment was rated by patients/caregivers as good or excellent for 
85.7% of bleeds. Most bleeds were trauma related (n = 8, 63.0%), 
and most occurred in joints (n = 56, 40.0%), skin/mucosa (n = 41, 
29.3%) or muscle (n = 26, 18.6%). Mean ± SD (range) dose to treat 
bleeds was 46.8 ± 11.3 (21-71) IU/kg per infusion.
In Part 2, eight patients completed the study and were included 
in the ABR evaluation. These patients had a total of nine bleeds (four 
traumatic, five spontaneous), corresponding to an ABR (Q1; Q3) of 
2.4 (0-6.9; Table 2 and Figure 3); median ABRs (Q1; Q3) for joint 
bleeds and spontaneous bleeds were 0.0 (0.0; 2.4) and 0.0 (0.0; 2.2), 
respectively. All bleeds were controlled with a single infusion of BAY 
94-9027.
3.2 | Safety
In Part 1 of the study, BAY 94-9027 was well tolerated by the ma-
jority of patients for more than 50 EDs. There was no evidence of 
increased plasma-free PEG levels in Part 1; all PEG levels were below 
the LLOQ. No FVIII inhibitors were reported in Part 1 or Part 2.
Overall, 12 patients discontinued (eight from Part 1; four from Part 
2); 11 were <6 years (Table S1). One patient discontinued due to the 
parent's decision and perceived lack of efficacy (Table S1) but no AEs 
were reported. All other discontinuations were related to perceived 
loss of efficacy and/or hypersensitivity reactions that occurred with 
the first four EDs; all AEs in patients who withdrew were transient, did 
not require intervention, and resolved when patients resumed treat-
ment with their previous FVIII product. Of four patients who with-
drew from Part 2 of the study, one tested positive for IgM anti-PEG 
antibodies at screening (Week −6-0) but not at baseline or during the 
study. Two patients tested positive for these antibodies at baseline and 
during the study, and one tested positive only during the study. No 
anti-PEG or anti-BAY 94-9027 antibodies were detected at the end 
of the study in patients who completed Part 2. One patient in Part 1 
who had no pre-treatment anti-PEG antibody tested positive during 
treatment and at the final assessment (Table 3); these were short-lived 
anti-PEG IgM antibodies that disappeared when the patient resumed 
F I G U R E  2   Patient disposition and treatment regimens during Part 1 and Part 2 PROTECT VIII Kids study. Arrows show movement of 
patients between regimens and do not reflect the time during the study when the switch occurred. *6 patients aged <6 y switched from 
every-7-d dosing to every-5-d dosing, one of these patients switched again from every-5-d dosing to twice-weekly regimen; †1 patient aged 
6-<12 y switched from every-5-d dosing to every-7-d dosing; ‡1 patient aged 6-<12 y switched from every-7-d dosing to twice-weekly, 
and 1 patient in the same group switched from every-7-d to every-5-d dosing; §1 patient discontinued after receiving 1 dose of BAY 94-
9027 and was not included in the efficacy evaluation, but was included in the safety population. y, years
Part 1 Part 2
Initial dosing
frequency
Final dosing
frequency
at study
completion
Twice weekly
n = 6
Twice weekly
n = 11
Every 5 d
n = 13
Every 5 d
n = 15
Every 7 d
n = 6
Every 7 d
n = 2
Twice weekly
n = 8
Discontinued
n = 3
Discontinued
n = 0
Discontinued
n = 4
Discontinued
n = 0
Discontinued
n = 0
Discontinued
n = 1§
Age <6 y
n = 8
Age 6-12 y
n = 10
Age <6 y
n = 12
Age 6-12 y
n = 15
Age <6 y
n = 12
n = 1†
n = 5*
n = 1‡
n = 1‡
n = 1*
Age 6-12 y
n = 4
Discontinued
n = 4
Every 5 d
n = 27
Every 7 d
n = 16
Twice weekly
n = 12
Twice weekly
n = 18
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F I G U R E  3   Summary of bleeds and BAY 94-9027 consumption by regimen in all patients who completed Part 1 (n = 53) and Part 2 
(n = 8) of the study. Panel A, patients aged <6 y; Panel B, patients aged 6-<12 y. *Patients who changed dosing frequency (increased or 
decreased). ABR, annualized bleeding rate; Q1, quartile 1; Q3, quartile 3; SD, standard deviation; y, years
1.9
3.0
1.4
5.7
2.5 2.4
0 0 0
1.4
0 00
1.4
0.5
1.4 1.2
0
1.7
M
ed
ia
n 
A
B
R
2.2
1.1
2.8
1.7
2.2
0
2
4
6
8
10
12
Twice weekly 
(n = 5)
Every 5 d
(n = 8)
Every 7 d
(n = 6)
Part 1 Part 2
Changed
frequency (n = 6)*
Total
(N = 25)
Twice weekly
(n = 8)
Twice weekly Every 5 d Every 7 d
Part 1
Prophylaxis frequency
Part 2
Changed
frequency Total Twice weekly 
1.7; 2.0 1.3; 4.9 1.1; 4.8 2.5; 7.1 1.2; 5.2 0; 6.9
1.0 (1.0; 1.0) 2.0 (1.0; 3.5) 1.5 (1.0; 5.0) 3.5 (2.0; 5.0) 2.0 (1.0; 4.0) 0.5 (0; 1.5)
4218 ± 1020
(n = 5)
Q1; Q3 for all bleeds
Median number
of all bleeds (Q1; Q3)
Mean ± SD total
dose in patients
aged <6 y, IU/kg/y
4149 ± 513
(n = 8)
3189 ± 178
(n = 6)
4295 ± 437
(n = 6)
3967 ± 706
(N = 25)
4933 ± 931
(n = 8)
All Bleeds Spontaneous bleeds Joint bleeds Trauma bleeds
M
ed
ia
n 
A
B
R
0
2
4
6
8
10
12
1.0 1.0
0 0
Twice weekly 
(n = 10)
3.0
1.5
0.8 0.7
Every 5 d
(n = 14)
2.2
1.1
0
1.1
Every 7 d
(n = 1)
Part 1 Part 2
10.6
5.5
1.8
2.7
Changed
frequency (n = 3)*
2.9
1.5
0
0.6
Total
(N = 28)
Twice weekly Every 5 d Every 7 d
Part 1
Prophylaxis frequency
Changed
frequency Total
0; 5.6 1.4; 6.1 2.2 1.4; 11.0 0; 6.7
0.5 (0; 3.0) 2.0 (1.0; 4.0) 2.0 6.0 (1.0; 8.0) 2.0 (0; 4.0)
3113 ± 697
(n = 10)
Q1; Q3 for all bleeds
Median number
of all bleeds (Q1; Q3)
Mean ± SD total
dose in patients aged
6 to <12 y, IU/kg/y
3715 ± 579
(n = 14)
3511
(n = 1)
3866 ± 616
(n = 3)
3509 ± 667
(N = 28)
(A)
(B)
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their previous FVIII treatment. No anti-PEG IgE antibodies were de-
tected in the patients who withdrew due to hypersensitivity reactions.
In Part 1, 50 of 61 patients (82%) who received BAY 94-9027 
reported AEs (Table 4), the majority of which were of mild or mod-
erate intensity. Nine patients (<6 years, n = 7; 6-<12 years, n = 2) 
experienced AEs that were assessed by the investigator as related 
to BAY 94-9027 (aged <6 years: moderate hypersensitivity, n = 2; 
spontaneous haemorrhage, n = 1; spontaneous haematoma, n = 1; 
subcutaneous haematoma, n = 1; contusion, n = 1; dysgeusia, n = 1. 
Aged 6-<12 years: moderate hypersensitivity, n = 1; epistaxis, 
TA B L E  2   Summary of bleeds by age group and dosing frequency in Part 1 and Part 2 of the study (study completers)
 
Dosing Frequency Part 1
Dosing 
Frequency Part 2
Twice-weekly Every 5 d Every 7 d Changed frequencya  Total Twice-weekly
Patients aged <6 y, n 5 8 6 6 25 8
Number of all bleeds 1.0 (1.0; 1.0) 2.0 (1.0; 3.5) 1.5 (1.0; 5.0) 3.5 (2.0; 5.0) 2.0 (1.0; 4.0) 0.5 (0; 1.5)
ABR for all bleeds 1.9 (1.7; 2.0) 3.0 (1.3; 4.9) 1.4 (1.1; 4.8) 5.7 (2.5; 7.1) 2.5 (1.2; 5.2) 2.4 (0; 6.9)
ABR for spontaneous bleeds 0 (0; 0) 0 (0; 1.4) 0 (0; 0.8) 1.4 (0; 3.0) 0 (0; 1.3) 0 (0; 2.2)
ABR for joint bleeds 0 (0; 1.7) 1.36 (0; 1.5) 0.5 (0; 1.6) 1.4 (0; 2.5) 1.24 (0; 1.6) 0 (0; 2.4)
ABR for trauma bleeds 1.7 (0; 2.0) 2.2 (1.3; 3.5) 1.1 (0.8; 4.8) 2.8 (1.7; 4.3) 1.7 (1.1; 3.9) 2.2 (0; 4.6)
Patients with 0 bleeds, n (%) 1 (20.0) 1 (12.5) 1 (16.7) 1 (16.7) 4 (16.0) 4 (50.0)
Patients aged 6-<12 y, n 10 14 1 3 28  
Number of all bleeds 0.5 (0; 3.0) 2.0 (1.0; 4.0) 2.0 6.0 (1.0; 8.0) 2.0 (0; 4.0)  
ABR for all bleeds 1.0 (0; 5.6) 3.0 (1.4; 6.1) 2.2 10.6 (1.4; 11.0) 2.9 (0; 6.7)  
ABR for spontaneous bleeds 1.0 (0; 3.8) 1.5 (0; 2.8) 1.1 5.5 (0; 8.0) 1.5 (0; 3.0)  
ABR for joint bleeds 0 (0; 2.0) 0.8 (0; 2.9) 0 1.8 (0; 4.0) 0 (0; 2.8)  
ABR for trauma bleeds 0 (0; 1.9) 0.7 (0; 2.9) 1.1 2.7 (1.4; 5.5) 0.6 (0; 2.7)  
Patients with 0 bleeds, n (%) 5 (50.0) 3 (21.4) 0 (0) 0 (0) 8 (28.6)  
Note: Data are median (quartile 1; quartile 3) unless otherwise indicated.
Abbreviations: ABR, annualized bleeding rate; y, years.
aPatients who changed dosing frequency (increased or decreased). 
F I G U R E  4   Annualized bleeding rates in patients who increased dosing frequency in Part 1 of the study. a8 patients increased dosing 
frequency from every 7 d to every 5 d (n = 6) or twice-weekly (n = 2). ABR, annualized bleeding rate; Q1, quartile 1; Q3, quartile 3
All bleeds
12.3; 29.2
0.7; 5.3
Spontaneous bleeds
0; 16.3
0; 1.0
Joint bleeds
1.0; 12.9
0; 0.7
Trauma bleeds
0; 18.4
0; 2.6
Q1; Q3 for all bleeds before switching
Q1; Q3 for all bleeds after switching
M
ed
ia
n 
A
B
R
0
5
10
15
20
All bleeds Spontaneous bleeds Joint bleeds Trauma bleeds
18.3
2.6
8.9
0
4.8
0
6.4
1.7
Before switching (n = 8)a After switching (n = 8)a
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n = 1). Six of these patients experienced serious AEs (moderate 
hypersensitivity, n = 2 aged <6 years and n = 1 aged 6-<12 years; 
anti-drug antibodies [not FVIII inhibitor], n = 3 aged <6 years).
In Part 2, 11 (92%) patients reported mild or moderate AEs, four 
of which were related to BAY 94-9027 (loss of efficacy; n = 3; hyper-
sensitivity, n = 1) and two patients reported serious AEs (moderate 
hypersensitivity, n = 1; loss of efficacy, n = 1).
4  | DISCUSSION
BAY 94-9027 was efficacious for prophylaxis and treatment of 
bleeds in patients <12 years with severe haemophilia A, particularly 
when administered twice-weekly and every 5 days. No FVIII inhibi-
tors were reported. Because the dosing regimens were at the dis-
cretion of the treating physician and were modified based on the 
needs of the individual patient, the study design reflects a real-world 
approach to prophylaxis; factors including level of physical activity 
and adherence14-16 were taken into consideration when developing 
this dosing regimen. The open-label design and relatively short dura-
tion are potential limitations of this study, but are consistent with 
recent clinical studies in children for other EHL FVIII products.17-19
Most patients in Part 1 who completed the study remained at 
their initial dosing frequency. Of nine patients who switched, eight 
switched to a more-frequent dosing schedule; in all patients who 
switched, bleeding control was maintained or improved. Switching 
to a more-frequent dosing schedule was expected for two reasons. 
Firstly, investigators were encouraged to start their patients on the 
least-frequent infusion schedule appropriate for that patient, and a 
switch in dosing schedule was allowed at any time. Secondly, the half-
lives of both standard half-life and EHL FVIII products are shorter 
in patients <12 years, compared with adolescents and adults, and 
so longer dosing intervals may not be as successful in children.19-22 
However, the ability of BAY 94-9027 to extend dosing frequencies 
F I G U R E  5   Summary of bleeds in the first and last 90 d for patients who completed Part 1 of the study. aPatients who changed dosing 
frequency (increased or decreased) during the indicated time period. ABR, annualized bleeding rate; N/A, not applicable; Q1, quartile 1; 
Q3, quartile 3; y, years
Q1; Q3 for all bleeds
First 90 d of the study
Q1; Q3 for all bleeds
Last 90 d of the study
Q1; Q3 for all bleeds
First 90 d of the study
Q1; Q3 for all bleeds
Last 90 d of the study
Patients aged <6 y
Patients aged 6 to <12 y
Twice weekly
0; 4.1
0; 4.1
0; 8.1
0; 4.1
Every 5 d
2.0; 4.1
0; 4.1
0; 8.1
0; 4.1
Every 7 d
0; 4.1
0; 8.1
0; 8.1
N/A
Changed
frequency
4.1; 12.2
N/A
N/A
0; 12.2
Total
0; 4.1
0; 4.1
0; 8.1
0; 4.1
First 90 d Last 90 d
M
ed
ia
n 
A
B
R
0
5
10
15
20
25
Twice
weekly
(n = 5)
0
2.0
4.1
0
4.1 4.1
12.2
N/A
4.1
0
Every
5 d
(n = 8)
Every
7 d
(n = 6)
Changed
frequency
(n = 6)a
Total
(N = 25)
Patients aged <6 y
Prophylaxis frequency
M
ed
ia
n 
A
B
R
0
5
10
15
20
25
Twice
weekly
(n = 10)
0 0
4.1
2.0
4.1 4.1
24.4
6.1
2.0
0
Every
5 d
(n = 15)
Patients aged 6 to <12 y
Prophylaxis frequency
Every
7 d
(n = 2)
Changed
frequency
(n = 1)a
Total
(N = 28)
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beyond twice-weekly in paediatric patients was apparent: effective 
protection from bleeds was observed in the seven patients who 
remained on every-7-day prophylaxis (median ABR = 1.4 for six 
patients <6 years and 2.2 for the one patient 6-12 years), and every-
5-day prophylaxis was the most frequently used regimen at the be-
ginning and end of the study (45% and 53% of patients, respectively).
Eight (13.1%) patients in Part 1 (<6 years, n = 7) and four (33.3%) 
patients in Part 2 discontinued BAY 94-9027 because of perceived 
loss of efficacy/hypersensitivity, occurring within the first four EDs; 
the majority of these patients (11/12, 91.7%) were aged <6 years. 
All of these patients were able to safely resume their previous FVIII 
therapy. Anti-PEG antibodies were detected in some of these pa-
tients prior to BAY 94-9027 exposure, but also in patients who did 
not experience AEs or loss of efficacy. Antibodies to PEG were ex-
clusively IgM with no evidence of class switching, and the immune 
response did not persist after patients resumed their previous FVIII 
treatment.
Lack of efficacy relating to formation of anti-drug antibodies has 
been observed with non-FVIII replacement therapies that do not con-
tain PEG. In the HAVEN 2 trial (NCT02795767) investigating emici-
zumab in patients aged <12 years with haemophilia A and inhibitors, 
one patient developed a clinically significant anti-drug antibody to 
emicizumab, resulting in loss of efficacy and eventual drug discontin-
uation.23,24 Thus, all biological treatments including FVIII replacement 
and non-replacement therapy carry a certain risk of immunogenicity in 
paediatric patients and further investigation and caution are necessary.
The detection of anti-PEG antibodies, before and following ex-
posure to PEGylated rFVIII, has been previously reported in children 
and adults. In the pathfinder 5 paediatric study, 31% of patients had 
anti-PEG antibodies before treatment with PEGylated turoctocog 
 
Anti–BAY 94-9027 Anti-PEG IgM Anti-PEG
N = 73 N = 73 N = 73
Pre-treatment positive, n (%) 7 (9.6) 3 (4.1) 13 (17.8)
Negative during treatment 4 (57.1) 3 (100.0) 7 (53.8)
Positive during treatmenta  3 (42.9) – 6 (46.2)
Still positive at last 
measurement
1 (33.3) – 3 (50.0)
Pre-treatment negative, n (%) 66 (90.4) 70 (95.9) 60 (82.2)
Missing during treatment 0 0 6 (10.0)
Negative during treatment 59 (89.4) 63 (90.0) 50 (83.3)
Treatment emergent 
positive
7 (10.6) 7 (10.0) 4 (6.7)
Still positive at last 
measurement
0 1 (14.3) 1 (25.0)
Abbreviation: PEG, polyethylene glycol.
aAny positive measurement during treatment. 
TA B L E  3   Combined results of antibody 
assays in Part 1 and Part 2 of the study 
(safety populations)
TA B L E  4   Patients with AEs considered treatment-related in Part 1 and 2 (safety populations)
Number of patients (%)
with AE
Part 1
Part 2
Aged < 6 y
(N = 12)
Combined
Part 1 and Part 2
(N = 73)
Aged < 6 y
(n = 32)
Aged 6-<12 y 
(n = 29)
Total
(N = 61)
Any AE 29 (90.6) 21 (72.4) 50 (82.0) 11 (91.7) 61 (83.6)
Any study drug-related AEa  7 (21.9) 2 (6.9) 9 (14.8) 4 (33.3) 13 (17.8)
Maximum intensity for any AE
Mild 13 (40.6) 13 (44.8) 26 (42.6) 7 (58.3) 33 (45.2)
Moderate 11 (34.4) 6 (20.7) 17 (27.9) 4 (33.3) 21 (28.8)
Severe 5 (15.6) 2 (6.9) 7 (11.5) – 7 (9.6)
Any SAE 8 (25.0) 3 (10.3) 11 (18.0) 2 (16.7) 13 (17.8)
Any study drug-related SAEa  5 (15.6) 1 (3.4) 6 (9.8) 2 (16.7) 8 (11.0)
Discontinuation of study drug 
due to AE
6 (18.8) 1 (3.4) 7 (11.5) 4 (33.3) 11 (15.1)
Abbreviations: AE, adverse event; SAE serious adverse event.
aAs judged by the investigator. 
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alfa (Espercot®; Novo Nordisk) and one patient developed anti-PEG 
antibodies after exposure; no impact of these antibodies on safety 
or efficacy of treatment was reported.18 In the phase 3 trial of BAX 
855 (Adynovate®; Baxalta US Inc) in children <12 years, five patients 
(7.6%) reported anti-PEG antibody (IgG) development during treat-
ment,25 while in the PROLONG-ATE study of BAX 855 in adoles-
cents and adults with haemophilia A, three patients (2.2%) developed 
anti-PEG antibodies.17 The occurrence of anti-PEG antibodies is not 
exclusive to haemophilia and rFVIII products. There are currently 20 
PEGylated compounds approved for a variety of clinical indications.26 
The presence of antibodies to the PEG moiety has been associated 
with accelerated drug clearance resulting in loss of efficacy.27,28 An 
extensive review of safety data for PEGylated therapies showed no 
specific association between particular AEs and PEG exposure over 
a period of decades.26 No long-term PEG-related safety concerns 
have been reported in patients after chronic treatment with other 
PEGylated proteins, including nonacog beta pegol and certolizumab 
pegol.29 Long-term exposure data with BAY 94-9027 over 5 years 
has been reassuring, and more long-term data will soon be available 
from the PROTECT VIII Kids extension study. Hypersensitivity reac-
tions associated with other FVIII products are uncommon.7,30
Recently published preclinical investigations in rats have demon-
strated that a mechanism for PEG excretion exists, even for higher 
molecular weight PEG molecules, such as the PEG-60 moiety in 
BAY 94-9027. Following degradation of the protein, free PEG is 
distributed, reaching a steady state in plasma after approximately 
1 year; subsequently, no further increases in PEG in plasma are ob-
served.31,32 In PROTECT VIII Kids, no increases in free PEG were 
observed in the plasma of patients treated in Part 1. The long-term 
efficacy and safety of BAY 94-9027 are currently under investiga-
tion in children continuing treatment for >5 years; preliminary re-
sults suggest that there is no increase in plasma PEG levels over 
time (assessed every 6 months for up to 6 years) and no PEG-related 
safety concerns.13
5  | CONCLUSIONS
Using a study design that allowed tailoring of prophylaxis regimens 
to individualized patient response, BAY 94-9027 was effective for 
the prevention and treatment of bleeding episodes in previously 
treated patients aged <12 years with severe haemophilia. A total of 
61 patients completed the study, with 59 continuing into the exten-
sion. For those patients who remained in the study, BAY 94-9027 
was well tolerated and no FVIII inhibitors developed.
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